Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of CKD-333 vs CKD-330 + D086 in Healthy Males
NCT03659149Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Aug 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of candesartan + amlodipine + atorvastatin in hypertension (HTN) and dyslipidemia (6 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area under the plasma drug concentration-time curve from time 0 to time t and Maximum plasma concentration. Started Aug 2018; status: completed.
02
Drugs
candesartan + amlodipine + atorvastatin
03
Conditions
hypertension (HTN)dyslipidemia
Beyond the preview
Go deeper on NCT03659149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03659149.